RhumbLine Advisers
RPRX icon

RhumbLine Advisers’s Royalty Pharma RPRX Stock Holding History

RhumbLine Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1M Buy
484,183
+24,885
+5% +$1.3M 0.02% 610
2026
Q1 		$22M Sell
459,298
-6,049
-1% -$265K 0.02% 667
2025
Q4 		$18M Buy
465,347
+16,204
+4% +$618K 0.01% 762
2025
Q3 		$15.8M Buy
449,143
+1,903
+0.4% +$68.9K 0.01% 860
2025
Q2 		$16.1M Sell
447,240
-2,724
-0.6% -$90.2K 0.01% 821
2025
Q1 		$14M Sell
449,964
-4,184
-0.9% -$133K 0.01% 870
2024
Q4 		$11.6M Sell
454,148
-3,362
-0.7% -$89.1K 0.01% 985
2024
Q3 		$12.9M Buy
457,510
+10,429
+2% +$289K 0.01% 945
2024
Q2 		$11.8M Sell
447,081
-11,165
-2% -$309K 0.01% 950
2024
Q1 		$13.9M Buy
458,246
+2,490
+0.5% +$73.4K 0.01% 888
2023
Q4 		$12.8M Sell
455,756
-5,543
-1% -$152K 0.01% 928
2023
Q3 		$12.5M Sell
461,299
-14,018
-3% -$416K 0.01% 882
2023
Q2 		$14.6M Buy
475,317
+57,011
+14% +$1.93M 0.02% 809
2023
Q1 		$15.1M Buy
418,306
+7,164
+2% +$266K 0.02% 755
2022
Q4 		$16.2M Buy
411,142
+24,889
+6% +$1.04M 0.02% 693
2022
Q3 		$15.5M Buy
386,253
+41,475
+12% +$1.77M 0.02% 660
2022
Q2 		$14.5M Buy
344,778
+67,171
+24% +$2.75M 0.02% 710
2022
Q1 		$10.8M Sell
277,607
-5,056
-2% -$199K 0.01% 918
2021
Q4 		$11.3M Buy
282,663
+10,161
+4% +$395K 0.01% 924
2021
Q3 		$9.85M Sell
272,502
-16,754
-6% -$651K 0.01% 964
2021
Q2 		$11.9M Sell
289,256
-7,547
-3% -$321K 0.02% 900
2021
Q1 		$12.9M Buy
296,803
+199,442
+205% +$9.46M 0.02% 836
2020
Q4 		$4.87M Buy
97,361
+20,592
+27% +$874K 0.01% 1367
2020
Q3 		$3.23M Buy
+76,769
New +$3.29M 0.01% 1421

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's RPRX Position: Q2 2026 in Review

RhumbLine Advisers increased its Royalty Pharma (RPRX) stake by 5.4% in Q2 2026, buying an estimated $1.3M and bringing the position to 484,183 shares worth $27.1M. The position accounts for 0.02% of the portfolio, ranked #610.

RhumbLine Advisers first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • RhumbLine Advisers held 484,183 shares of Royalty Pharma worth $27.1M as of Q2 2026.
  • RhumbLine Advisers bought 24,885 Royalty Pharma shares in Q2 2026, an estimated $1.3M.
  • Royalty Pharma made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #610 holding.
  • RhumbLine Advisers first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.